Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for AMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 -0.2495M
March 31, 2026 -1.684M
December 31, 2025 -0.0014M
September 30, 2025 -0.24M
June 30, 2025 -0.674M
March 31, 2025 -1.123M
December 31, 2024 0.023M
September 30, 2024 -0.0741M
June 30, 2024 0.0328M
March 31, 2024 -1.425M
December 31, 2023 0.0832M
September 30, 2023 -0.279M
June 30, 2023 0.0594M
March 31, 2023 0.3673M
December 31, 2022 0.0339M
September 30, 2022 -0.1533M
June 30, 2022 0.2427M
March 31, 2022 -0.5021M
December 31, 2021 -0.1842M
September 30, 2021 -0.1178M
June 30, 2021 0.4405M
March 31, 2021 -5.211M
December 31, 2020 -5.842M
September 30, 2020 -13.44M
June 30, 2020 -14.21M
Date Value
March 31, 2020 -25.87M
December 31, 2019 -18.21M
September 30, 2019 434.01M
June 30, 2019 -4.438M
March 31, 2019 -0.0475M
December 31, 2018 200.06M
September 30, 2018 8.023M
June 30, 2018 -2.940M
March 31, 2018 65.65M
December 31, 2017 -3.353M
September 30, 2017 -0.0058M
June 30, 2017 0.4394M
March 31, 2017 11.24M
December 31, 2016 1.394M
September 30, 2016 61.94M
June 30, 2016 0.0804M
March 31, 2016 -0.7198M
December 31, 2015 13.07M
September 30, 2015 6.544M
June 30, 2015 1.631M
March 31, 2015 50.84M
December 31, 2014 -2.307M
September 30, 2014 4.896M
June 30, 2014 -2.525M
March 31, 2014 0.2696M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 121.80M
Alkermes Plc 17.20M
Cellectis SA -3.157M
Akari Therapeutics Plc 8.034M
Liquidia Corp. -6.614M